Every 39 mg/dL (1mmol/L) reduction in LDL-C9
22% risk reduction in major CV event9
On December 6th, the Dubai Health Authority, Emirates Cardiac Society, World Heart Federation united with Amgen to raise awareness on cholesterol and other risk factors that increase the risk of heart attacks and strokes, while encouraging people to eat healthy and exercise regularly. The public was invited to receive free cholesterol screenings onsite and view a video broadcast on the world’s tallest tower – Burj Khalifa. More than 1500 people took part in the free cholesterol screening.
1. World Health Organization. Prevention of Recurrences of Myocardial Infarction and Stroke Study The PREMISE programme: country projects. Available at: http://www.who.int/cardiovascular_diseases/priorities/secondary_prevention/country/en/index1.html. Last accessed June 2018. 2. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatientsat risk of or with atherothrombosis. JAMA.2010;304:1350-1357. 3. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. 4. Goldstein JL, Brown MS. The LDL Receptor. Arterioscler Thromb Vasc Biol. 2009;29(4);431–438. 5. Hansson GK, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16);1685-1695. 6. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22);1371-1375. 7. Waters DD, Brotons C, Chiang CW, et al; Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1);28-34. 8. Fox K, Kostev K, Vultee C, et al. Lack of low-density lipoprotein cholesterol (LDL-C) goal attainment among high-risk patients using high or moderate intensity statin therapy in Germany. Eur Heart J. 38. 10.1093/eurheartj/ehx502.P2320. 9. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1);1-10. 10. Gitt A, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016;255;200-209. 11. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5);485-494. 10.1016/j.jacc.2014.02.615.